Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

US FDA gives green light for use of AstraZeneca's Voydeya

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH). PNH is a condition under which some patients' immune systems destroy a larger proportion of red blood cells than they should, whilst EVH is the condition in which red blood cells outside of blood vessels were destroyed.

Voydeya could now be used as an add-on therapy to ravulizumab or eculizumab to treat EVH in adults with PNH.

The drug was a first-in-class, oral, Factor D inhibitor meant to address the needs of the roughly 10-20% of patients with PNH experiencing "clinically significant" EVH when they were being treated with a C5 inhibitor.

Share this article

Related Sharecast Articles

Tritax Eurobox says Brookfield offer deadline extended; in talks with other parties
(Sharecast News) - Tritax Eurobox rallied on Tuesday after it said the deadline for Brookfield Asset Management to make an offer for the company has been extended, and that it had received other expressions of interest from a number of parties.
Caspian Sunrise reports progress on several fronts
(Sharecast News) - Caspian Sunrise updated the market on its recent activities on Tuesday, including well testing results, new drilling, and preparations for the charter of the Caspian Explorer.
Tesla shares pop on better-than-expected delivery numbers
(Sharecast News) - Tesla shares were rising on Tuesday, after it reported a smaller-than-expected decline in vehicle deliveries for the second quarter on the back of strategic price cuts and incentives designed to boost demand.
CleanTech announces results of plant location study
(Sharecast News) - CleanTech Lithium announced the results of a plant location study on Tuesday, as part of the ongoing pre-feasibility study (PFS) for its Laguna Verde Project in Chile.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.